DAIC

FEBRUARY 27, 2024

milla1cf Tue, 02/27/2024 - 17:29 February 27, 2024 — Aria CV, Inc , a developer of medical devices treating pulmonary hypertension, today announced the first patient was implanted with the Gen 2 Aria CV Pulmonary Hypertension System as part of the ASPIRE PH clinical trial at Ascension St. Ashwin Ravichandran and Scott Hittinger.

Pulmonary 110

Pulmonary Hypertension Heart Failure Blood Pressure 110

Open Heart

OCTOBER 19, 2022

However, right heart dysfunction as well as the proportion of patients with severe tricuspid regurgitation remained unchanged. Clusters with persistent right heart dysfunction ultimately displayed 2-year survival rates of 69.2% (95% CI 56.6% ±15.8 ±15.1 mm Hg, p value: 0.0079). to 84.7%) and 74.6% (95% CI 65.9%

Aortic valve 52

Aortic valve Aortic Stenosis TAVR 52

Dr. S. Venkatesan MD

AUGUST 3, 2024

However, It is surprising even in chronic pulmonary hypertension , the degree of RVH is not constant and homogenous.This is because , different parts of RV chamber has different wall thickness.Further, the pressure distribution from PA to RV is uneven. This may be correct when there is acute raise in RV after load, as in PE.

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Pulmonary Heart Dysfunction 52